SDGR Q1 2023 Earnings — Schrödinger, Inc. Revenue & Financial Results | Market Cap Arena

SDGRSchrödinger, Inc.

$935M

Q1 2023 Earnings

Healthcare Medical - Healthcare Information Services

Income Statement

Revenue

$65M+33.1% YoY

Gross Profit

$46M70.5% margin

Operating Income

-$31M-47.1% margin

Net Income

$129M199.3% margin

EPS (Diluted)

$1.75

QoQ Revenue Growth

+14.0%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$35M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$839M

Total Liabilities

$249M

Stockholders' Equity

$590M

Cash & Equivalents

$233M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$65M	$49M	+33.1%
Gross Profit	$46M	$28M	+63.3%
Operating Income	-$31M	-$29M	-6.5%
Net Income	$129M	-$34M	+475.0%

Revenue Segments

Drug Discovery

$33M25%

Software Products And Services

$32M25%

Drug Discovery Services Revenue From Contracts With Customers

$32M24%

On Premise Software

$20M15%

Maintenance

$6M4%

Hosted Software

$4M3%

Drug Discovery Services

$2M2%

Professional Services

$2M2%

Geographic Segments

UNITED STATES

$50M78%

Europe

$7M10%

JAPAN

$4M7%

Non-US

$3M5%